DWTX

SEC source: 0001424620-26-000002 · form4-06172026_050642.xml · derivative · entry 1

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2036-06-16

SEC source: 0001825983-26-000001 · form4-06172026_050629.xml · derivative · entry 1

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2036-06-16

SEC source: 0001825986-26-000002 · form4-06172026_050656.xml · derivative · entry 1

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2036-06-16

SEC source: 0001441661-26-000002 · form4-06172026_050636.xml · derivative · entry 1

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

Underlying: Common Stock · 16,800 shares

Expires 2036-06-16

SEC source: 0001826084-26-000002 · form4-03062026_090358.xml · derivative · entry 1

Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2036-03-05

F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

SEC source: 0001825987-26-000002 · form4-03062026_090340.xml · derivative · entry 1

Walsh Angela · CIK 0001825987 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2036-03-05

F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

SEC source: 0001826131-26-000002 · form4-03062026_090328.xml · derivative · entry 1

Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2036-03-05

F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

SEC source: 0001831127-26-000005 · form4-03062026_090335.xml · derivative · entry 1

Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,000

Underlying: Common Stock · 330,000 shares

Expires 2036-03-05

F1 · derivative.exercise_date: The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

SEC source: 0001831127-25-000005 · form4-12052025_041207.xml · derivative · entry 1

Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 460,000

Underlying: Common Stock · 460,000 shares

Expires 2035-12-04

F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter.

SEC source: 0001826084-25-000005 · form4-12052025_041203.xml · derivative · entry 1

Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-12-04

F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter.

SEC source: 0001825987-25-000005 · form4-12052025_041205.xml · derivative · entry 1

Walsh Angela · CIK 0001825987 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-12-04

F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter.

SEC source: 0001826131-25-000005 · form4-12052025_041201.xml · derivative · entry 1

Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-12-04

F1 · derivative.exercise_date: The stock option vests one-third on December 4, 2026 and 1/24th monthly thereafter.

SEC source: 0001104659-25-116066 · tm2532101-2_4seq1.xml · derivative · entry 4

Sealbond Ltd · CIK 0002040446 · Director · 10% owner · See Remarks

Conjoint Inc. · CIK 0002061651 · Director · 10% owner · See Remarks

CK Life Sciences Intl (Holdings) Inc · CIK 0001297567 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Conjoint Inc.

Disclosed balance after: 0

Underlying: Common Stock · 2,842,638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · kind: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001104659-25-116066 · tm2532101-2_4seq1.xml · derivative · entry 3

Sealbond Ltd · CIK 0002040446 · Director · 10% owner · See Remarks

Conjoint Inc. · CIK 0002061651 · Director · 10% owner · See Remarks

CK Life Sciences Intl (Holdings) Inc · CIK 0001297567 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,610,950 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · kind: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F4 · shares: Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · derivative.exercise_date: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F2 · ownership.direct: Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001104659-25-116066 · tm2532101-2_4seq1.xml · nonDerivative · entry 2

Sealbond Ltd · CIK 0002040446 · Director · 10% owner · See Remarks

Conjoint Inc. · CIK 0002061651 · Director · 10% owner · See Remarks

CK Life Sciences Intl (Holdings) Inc · CIK 0001297567 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Conjoint Inc.

Disclosed balance after: 2,842,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · price: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001104659-25-116066 · tm2532101-2_4seq1.xml · nonDerivative · entry 1

Sealbond Ltd · CIK 0002040446 · Director · 10% owner · See Remarks

Conjoint Inc. · CIK 0002061651 · Director · 10% owner · See Remarks

CK Life Sciences Intl (Holdings) Inc · CIK 0001297567 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,822,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F1 · price: On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

F2 · ownership.direct: Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001415889-25-018653 · form4-07012025_060708.xml · derivative · entry 1

Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,075

Underlying: Common Stock · 12,075 shares

Expires 2035-06-27

F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter.

SEC source: 0001415889-25-018648 · form4-07012025_060757.xml · derivative · entry 1

Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,075

Underlying: Common Stock · 12,075 shares

Expires 2035-06-27

F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter.

SEC source: 0001415889-25-018651 · form4-07012025_060726.xml · derivative · entry 1

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,362

Underlying: Common Stock · 2,362 shares

Expires 2035-06-27

SEC source: 0001415889-25-018645 · form4-07012025_060727.xml · derivative · entry 1

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,362

Underlying: Common Stock · 2,362 shares

Expires 2035-06-27

SEC source: 0001415889-25-018643 · form4-07012025_060730.xml · derivative · entry 1

Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-06-27

F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter.

SEC source: 0001415889-25-018640 · form4-07012025_050707.xml · derivative · entry 1

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,362

Underlying: Common Stock · 2,362 shares

Expires 2035-06-27

SEC source: 0001415889-25-018635 · form4-07012025_050721.xml · derivative · entry 1

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,362

Underlying: Common Stock · 2,362 shares

Expires 2035-06-27

SEC source: 0001415889-25-018638 · form4-07012025_050708.xml · derivative · entry 1

Walsh Angela · CIK 0001825987 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,075

Underlying: Common Stock · 12,075 shares

Expires 2035-06-27

F1 · derivative.exercise_date: The stock option vests one-third on June 27, 2026 and 1/24th monthly thereafter.

SEC source: 0001415889-25-017940 · form4-06232025_040610.xml · derivative · entry 2

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017940 · form4-06232025_040610.xml · derivative · entry 1

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017938 · form4-06232025_040645.xml · derivative · entry 2

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017938 · form4-06232025_040645.xml · derivative · entry 1

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017934 · form4-06232025_030604.xml · derivative · entry 2

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017934 · form4-06232025_030604.xml · derivative · entry 1

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017932 · form4-06232025_030627.xml · derivative · entry 2

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001415889-25-017932 · form4-06232025_030627.xml · derivative · entry 1

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210

Underlying: Common Stock · 210 shares

Expires 2035-06-18

SEC source: 0001104659-25-024577 · tm259598-1_4seq1.xml · derivative · entry 1

CK Life Sciences Intl (Holdings) Inc · CIK 0001297567 · Director · 10% owner · See Remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 284.2638

Underlying: Common Stock · 2,842,638 shares

Expires not disclosed

F2 · derivative.exercise_price: Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series A-1 Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

F3 · kind: On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the "Loan Agreement"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted.

F3 · price: On March 12, 2025, Conjoint entered into a Debt Exchange and Cancellation Agreement with the Issuer pursuant to which $19,500,000 in principal amount of all loans made to the Issuer under a Loan Agreement, dated October 7, 2024 (the "Loan Agreement"), between Conjoint and the Issuer, along with accrued interest through March 12, 2025 (as of such date, an aggregate of $19,926,891), was deemed repaid and all of the Issuer's obligations under the Loan Agreement with respect to the principal amount and accrued interest was satisfied in full and cancelled in exchange for 284.2638 shares of Series A-1 Preferred Stock, based on a price per underlying share of Common Stock of $7.01. This transaction involved an acquisition of shares in connection with a debt previously contracted.

F2 · derivative.exercise_date: Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series A-1 Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

F2 · derivative.expiration_date: Following stockholder approval of the conversion of the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ("Series A-1 Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of the Series A-1 Preferred Stock will be convertible into 10,000 shares of Common Stock, subject to waiver by Conjoint, as the direct holder of the shares, of a beneficial ownership limitation of 19.99% of the outstanding Common Stock. The shares of Series A-1 Preferred Stock have no expiration date. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

F1 · ownership.nature: Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC source: 0001415889-24-005686 · form4-02282024_060247.xml · derivative · entry 1

Pridgen William · CIK 0001826115 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,917

Underlying: Common Stock · 2,917 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005684 · form4-02282024_060238.xml · derivative · entry 1

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,167

Underlying: Common Stock · 4,167 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005679 · form4-02282024_060230.xml · derivative · entry 1

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,709

Underlying: Common Stock · 4,709 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005676 · form4-02282024_050222.xml · derivative · entry 1

Burch Richard Alan · CIK 0001837084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,917

Underlying: Common Stock · 2,917 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005681 · form4-02282024_060200.xml · derivative · entry 1

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005674 · form4-02282024_050213.xml · derivative · entry 1

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,959

Underlying: Common Stock · 3,959 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005672 · form4-02282024_050228.xml · derivative · entry 1

Walsh Angela · CIK 0001825987 · SVP OF FINANCE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,618

Underlying: Common Stock · 63,618 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005670 · form4-02282024_050234.xml · derivative · entry 1

Grosswald Ralph · CIK 0001826084 · SVP OF OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,568

Underlying: Common Stock · 62,568 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005668 · form4-02282024_050208.xml · derivative · entry 1

Gendreau Roger Michael · CIK 0001826131 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,085

Underlying: Common Stock · 88,085 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-24-005666 · form4-02282024_050227.xml · derivative · entry 1

Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,835

Underlying: Common Stock · 138,835 shares

Expires 2034-02-26

F1 · derivative.exercise_date: The stock option will vest 100% on February 26, 2025, one year following the grant date.

SEC source: 0001415889-23-012474 · form4-08222023_070830.xml · nonDerivative · entry 1

Pridgen William · CIK 0001826115 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · 401 (k) Account

Disclosed balance after: 52,045

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.26 to $1.36, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.nature: The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee.

SEC source: 0001415889-23-012375 · form4-08182023_070801.xml · nonDerivative · entry 1

Duncan Gregory Scott · CIK 0001831127 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,461

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.00 to $1.25, inclusive. The reporting person undertakes to provide Virios Therapeutics, Inc. ("Virios"), any security holder of Virios or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001415889-23-009993 · form4-06202023_060614.xml · derivative · entry 1

Keefer David R · CIK 0001825986 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date.

SEC source: 0001415889-23-009991 · form4-06202023_060650.xml · derivative · entry 1

De La Rosa Abel · CIK 0001825983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date.

SEC source: 0001415889-23-009989 · form4-06202023_060625.xml · derivative · entry 1

Thomas John C · CIK 0001424620 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date.

SEC source: 0001415889-23-009987 · form4-06202023_050630.xml · derivative · entry 1

Burch Richard Alan · CIK 0001837084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date.

SEC source: 0001415889-23-009985 · form4-06202023_050656.xml · derivative · entry 1

Whitley Richard James · CIK 0001441661 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 5,250 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option will vest 100% on June 15, 2024, one year following the grant date.